ambrey-geneticsambry-geneticsbmi-healthcareBMIbrca-test-ukbrcabupacardio-dxcolordowndownloadfacebookforwardhalio-dxhca-healthcareHCAhearticon-burgericon-closeicon-githubicon-twitternanostringnuffield-healthnuffieldoncodnaoncomarkribbonskylinevideovitality coloricon-github
BreastNext (17 genes) logo

Is BreastNext the right test for you? 

It is estimated that 266,000 women and 2,500 men will be diagnosed with breast cancer this year alone. If you are considered high risk, this specialist 17 gene panel can help you and your clinician assess the most appropriate screening and treatment for you.

You are considered to be at high risk if you have early-onset or multiple diagnoses of breast cancer, male breast cancer, and/or have a family history of disease.

To get this test you will first need a consultation with your clinician, then you can either:

  • Buy it directly from this website (this cost may be covered by your medical insurance).
  • Access it through your treating hospital/private healthcare provider.

This test is only available to those aged 18 years or above.

 

Why?Close tab

Helping you make decisions

Understanding whether you have a genetic predisposition to cancer allows you to make informed decisions about monitoring and treatment that can significantly decrease cancer risks and improve overall survival rates.

For example, you could decide at what age to have your first mammogram and breast MRI scan – and how frequently to have them in the future.

If you need to make urgent decisions about treatment – perhaps whether to have a lump removed or a full or partial mastectomy – this test can give you and your clinician the vital knowledge to make an informed decision.

It can also indicate if a new therapy called PARP inhibitor treatment might be appropriate for you.

For your family

It’s also important to share the test analysis with your family: because, there could be implications for them too. For example, if a man or woman carries a mutation in BRCA1 (one of the genes tested), each of their parents (mother and father), siblings (brothers and sisters) and children (sons and daughters) have a 50% chance of carrying the same mutation. Knowing if this gene mutation is in the family means everyone can ensure they receive regular monitoring and screening.

 

How?Close tab

What do I need to do?

It’s usually a simple ‘spit test’ – all we need is your saliva. You’ll receive a kit with clear instructions on giving your sample.

 

ProcessClose tab

Buying the test

Step 1:  There are two options:

  • Via your treating hospital/private healthcare provider (we have special arrangements with many healthcare providers to enable you to access this test, click here to see the list)
  • By clicking the ‘Buy direct now’ button above (the cost may be covered by your medical insurance – check your policy details)

Step 2: Collection of sample

We will liaise directly with your clinician and organise the collection of your sample and delivery to the laboratory.

Step 3: Analysis and reporting

Your sample will be analysed and a report will be generated, usually within four to five weeks of receipt of your sample in the laboratory.

Step 4: Results

Your clinician will receive the test report giving a clear indication of whether you are at risk of breast cancer or if you have already been diagnosed, what steps you – and possibly other members of your family – need to take next.

 

CliniciansClose tab

Is BreastNext the right test for your patient?

 

This is one of a number of tests we offer analysing genes significant in assessing risk for breast and other common cancers.

When to consider testing

  • Early-onset breast cancer (diagnosed <45 years of age)
  • Triple negative (ER-/PR-/HER2/neu-) breast cancer diagnosed <60 years of age
  • Ovarian, Fallopian tube, or primary peritoneal cancer at any age
  • Bilateral or multiple primary breast cancers
  • Male breast cancer at any age
  • Ashkenazi Jewish descent with breast cancer at any age
  • 3 or more cases of breast, ovarian, pancreatic, and/or high-grade prostate cancer at any age
  • Known BRCA1 or BRCA2 mutation in the family

 

Mutation Detection Rate*

 

 

 

 

 

 

 

*Excludes MUTYH carriers and CHEK2 p.l157T

Test Description

BreastNext analyzes 17 genes (listed above). All genes are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for PTEN (c.-1300 to c.-745). The BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) is detected by NGS and confirmed by PCR and agarose gel electrophoresis. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1 Gross deletion/duplication analysis for the covered exons and untranslated regions of all 17 genes is performed using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray.

 

1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.

This test is provided by:

Ambry Genetics

Frequently asked questions

Do I need a doctor to authorise this test?
Yes, your doctor will need to provide the sample required for this test
Will my health insurance cover the cost of this test?
Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
How soon do I get my results?
Usually within four to five weeks of receipt of your sample in the laboratory.
How accurate is the test?
Ambry follows advanced laboratory procedures and ensures quality control to deliver accurate results you can trust.